Last reviewed · How we verify
NCT03852654
18F-DCFPyL PET-CT Scan and Prostate Cancer
Phase 2, PHASE3 trial testing 18F-DCFPyL in Prostate Cancer Adenocarcinoma in 170 participants. Status unknown.
30 December 2019
Quick facts
| Lead sponsor | Lida Jafari |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 170 |
| Start date | 22 July 2018 |
| Primary completion | 30 December 2019 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 18F-DCFPyL — full drug profile →
Conditions studied
- Prostate Cancer Adenocarcinoma — all drugs for Prostate Cancer Adenocarcinoma →
Sponsor
Lida Jafari
Who can join
18 and older, male only, with Prostate Cancer Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary Objective: The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for initial staging of prostate cancer in Veterans compared to conventional imaging (99mTc-MDP bone scan and Diagnostic CT or MRI). The primary clinical endpoint of our study is the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease at initial staging. Secondary Objectives: Frequency of the change in primary treatment plan after initial staging.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Impact of <sup>18</sup>F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer.
Parikh NR, Tsai S, Bennett C, Lewis M, et al · · 2020 · cited 4× · PMID 33305100 · DOI 10.1016/j.adro.2020.08.014
Verify or expand the search:
- PubMed search for NCT03852654
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 18F-DCFPyL
Trials testing the same drug.
- NCT05616650 — Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor · Phase 2 · recruiting
- NCT05155046 — 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy · Phase 2 · recruiting
- NCT05095519 — Hepatocellular Carcinoma Imaging Using PSMA PET/CT · Phase 2 · active not recruiting
- NCT04727736 — 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer · Phase 2 · terminated
- NCT04390880 — 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer · Phase 2 · completed
Other recruiting trials for Prostate Cancer Adenocarcinoma
Currently open trials in the same condition.
- NCT06184464 — Prostatic Size Reduction Following of Leuprorelin Acetate · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03852654 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lida Jafari
- Last refreshed: 25 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03852654.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing